Thursday

11th Aug 2022

Opinion

A Covid-19 vaccine? Why licensing is so important

  • In order for a Covid-19 vaccine to be effective, everyone, everywhere has to have access to it (Photo: www.freeimages.co.uk)

Recent headlines that Oxford University's Covid-19 vaccine might be ready as soon as September was followed less than 48 hours later by news that Oxford had signed an exclusive worldwide licensing deal with Astra Zeneca.

But the announcement of the deal mentioned nothing about plans for pricing or access of the new vaccine.

Read and decide

Join EUobserver today

Become an expert on Europe

Get instant access to all articles — and 20 years of archives. 14-day free trial.

... or subscribe as a group

Once again, a large corporation seems set to win, with global public health losing out.

True public health benefit depends not just on the strength of immune response induced by the vaccine, but on its accessibility and affordability.

In order for a Covid-19 vaccine to be effective, everyone, everywhere has to have access to it. With multiple candidates racing for the finish line, and a rush of news stories mingling promise and concern, here are five core principles to help guide vaccine development in the coming months.

Principle 1

Public investment in Covid vaccine development should require hard commitments to public access. Over the coming year, at least $18bn in public and philanthropic funds are projected to be given to vaccine labs and manufacturers. Governments and other donors need to be attaching clear rules and conditions to help ensure global, equitable access. These must go beyond generic commitments to availability and include concrete conditions, such as "cost-plus" pricing (cost of manufacture plus a small "fair" return) to facilitate making vaccines free at point of use for everyone. If such rules had been attached to public funding of the Oxford vaccine, the agreement with Astra-Zeneca would not have been permissible.

Principle 2

Non-exclusive licensing is a must. Exclusive licensing promotes profits, not public health, leaving a single corporation to decide where a vaccine is available and at what price. With a global pandemic like Covid-19, we need the opposite—global, decentralised manufacturing enabled by non-exclusive licensing, so that vaccines can be produced at the volumes needed. In 2019, Astra Zeneca made close to $3bn in profit. They and other private sector actors should not have the power to decide who gets vaccine access and who doesn't.

Principle 3

Contracts and agreements on publicly funded vaccines must be transparent. Full transparency of vaccine related contracts and agreements should also be a condition of public investment. Oxford has apparently signed a deal to commercialise a potentially life-saving vaccine developed almost entirely with public funds with no contract details released, and no explanation on how this deal will impact people's lives and futures in the UK and globally.

Principle 4

Universities should prioritise universal benefit - not patents and profits - in medicines and vaccine research. Universities are major drivers of medical innovation. About a third of all new medicines and health technologies originate in academic labs. This key research role gives universities huge potential to advance global health if they choose to share medical breakthroughs under open, non-exclusive licenses or licenses that promote lower prices in low-and middle-income countries. Oxford, with an endowment of over $7.5bn and global standing as a leader in education, and other university research centres should respect and prioritise advancing the public good.

Principle 5

National dealmaking is an enemy of global pandemic control. Covid-19 has mobilised impressive government commitments, including funding of needed research and approval of critically needed economic aid packages. It has also provoked governments to hoard and stockpile personal protective equipment, active pharmaceutical ingredients that will be needed to make medicines, and other critical health supplies as they look out for "their own." The British government gave Oxford $25m for work on the vaccine two weeks before the deal with Astra-Zeneca - a company with headquarters in London - was announced. Is there a required percentage of production in the Oxford contract set aside for UK use, and how much vaccine will this leave for the rest of the world? We don't know, but should. For Covid vaccines to be fairly allocated, we need not country by country dealmaking, but a collective manufacturing and procurement mechanism—akin to the role that UNICEF plays in procurement and distribution of childhood vaccines.

The Oxford vaccine candidate is only one of many. The harsh lessons of the Oxford-Astra-Zeneca deal come early enough for us to avoid similar problems in the future.

How vaccines are licensed will mean as much as clinical trial results in determining whether they save lives.

Covid-19 has forced a reexamination of the importance of public health across the globe. Reinforcing public stewardship of vaccine research, manufacture and marketing is just as crucial for pandemic control.

Author bio

Roxana Bonnell is a senior advisor at Open Society's Public Health Program, and was involved in creating OSF's Access to Medicines Initiative over 15 years ago.

Disclaimer

The views expressed in this opinion piece are the author's, not those of EUobserver.

Agenda

EU vaccine fundraising kicks off This WEEK

Worldwide efforts will be made to find €7.5bn for a possible cure for Covid-19. The commission will also flesh out its estimates of the coming recession.

EU launches funding drive for Covid-19 vaccine

The European Commission launches on Monday an initiative to raise €7.5bn to speed up the development of vaccines, treatment and testing capacity, ensuring that is equally "available to everyone and at affordable prices" and avoiding nationalisms.

Will coronavirus change EU's pharma supply chain?

The European Commission vice-president Vera Jourova recognised that the EU's pharmaceutical sector had a 'morbid dependency' on third-country suppliers. But some experts from the pharma field have warned export bans undermine global supply chains.

Feature

Why developing countries may be last to get the vaccine

'The current standard for vaccines is to be kept at two to eight degrees and that is really tough in many developing countries when it can be up to 50 degrees outside,' warn experts on the challenges facing low-income countries.

EU silent on US buying up world's remdesivir supplies

The European Commission says it is in talks with the US biopharmaceutical company Gilead to secure supplies of remdesivir but won't provide any details. The comments follow the purchase of the world's supply by the United States.

Column

Global hunger crisis requires more than just the Odessa deal

International donors are playing hide and seek. Instead of stepping up their assistance programmes, richer nations are cutting overseas aid, or reallocating funds from other parts of the world towards the Ukraine crisis.

Exploiting the Ukraine crisis for Big Business

From food policy to climate change, corporate lobbyists are exploiting the Ukraine crisis to try to slash legislation that gets in the way of profit. But this is only making things worse.

Stakeholders' Highlights

  1. EFBWW – EFBH – FETBBConstruction workers can check wages and working conditions in 36 countries
  2. Nordic Council of MinistersNordic and Canadian ministers join forces to combat harmful content online
  3. European Centre for Press and Media FreedomEuropean Anti-SLAPP Conference 2022
  4. Nordic Council of MinistersNordic ministers write to EU about new food labelling
  5. Nordic Council of MinistersEmerging journalists from the Nordics and Canada report the facts of the climate crisis
  6. Council of the EUEU: new rules on corporate sustainability reporting

Join EUobserver

Support quality EU news

Join us